Drug MicroRNA Target genes Function Cell Lines In vivo modelsCitation
Docetaxel miR-100 Plk1 Chemosensitize lung adenocarcinoma cells to docetaxel Suppress cell proliferation, enhance apoptosis and cell cycle arrest in the G2/M phase of cell cycle Down-regulate in vivo cell proliferating ability SPC-A1, A549, NCI-H1299, SPC-A1/DTX Nude mice [102 ] miR-650 ING4 Confer docetaxel chemoresistance both in vitro and in vivo SPC-A1, NCI-H1299 Athymic BALB/c nude mice [105 ] Cisplatin miR-451 N/D Enhance DDP chemosensitivity Inhibit growth and enhance apoptosis A549 BALB/c nude mice [84 ] miR-31 ABCB9 Induced DDP resistance Antiapoptotic effect SPC-A1, LTEP-A2, NCI-H460, NCI-H1299 N/T [86 ] Paclitaxel miR-133a/b, miR-361-3p N/D Oncogenic miR inhibition reduces cell survival NCI-H1155, NCI-H1993, NCI-H358 N/T [91 ] miR-101 EZH2 Decrease proliferation and invasive ability of cells Sensitize cells to paclitaxel NCI-H226, A549, NCI-H358, 801D N/T [98 ] Gemcitabine miR-133b MCL-1, BCL-W Increase apoptosis Gemcitabine sensitivity A549, NCI-H23, NCI-H2172, NCI-H226, NCI-H522, NCI-H2009, NCI-H1703 N/T [111 ]
EGFR-TKI miR-30b/c miR-221/222 APAF-1, BIM Gefitinib-induced PARP cleavage Decrease cell viability Restore gefitinib sensitivity Calu-1, A549, PC-9, HCC827 N/T [123 ] miR-214 PTEN Oncogenic Knockdown sensitizes cells to gefitinib HCC827, HCC827/GR N/T [126 ] miR-133b EGFR Inhibit cell’s growth and invasion abilities Enhance EGFR-TKI sensitivity PC-9, A549, NCI-H1650, NCI-H1975 N/T [131 ] Curcumin miRNA-186* Caspase-10 Inhibits cell apoptosis Down-regulation of miR-186 by curcumin induces apoptosis A549, A549/DDP N/T [154 , 157 ]
TRAIL miR-221, miR-222 N/D Impair TRAIL-dependent apoptosis Induce TRAIL-resistance Calu-1, A549, NCI-H460 N/T [168 ] miR-34a, miR-34c PDGFR-
, PDGFR-
Augment TRAIL response Reduce migratory and invasive capacity of cells NCI-H460, A549, NCI-H1299, Calu-6 NCI-H1703, N/T [169 ] miR-212 PED Increase sensitivity to TRAIL Tumor suppressor Calu-1, NCI-H460 N/T [175 ] PRIMA-1 miR-34a N/D Induce apoptosis in the lung cancer cells containing mutant p53 A549, NCI-H211, NCI-H1155, NCI-H1299 N/T [148 ] Multidrug Resistance miR-200bc/429 BCL2, XIAP Enhanced sensitivity to various anticancer drugs including VCR, CDDP, VP-16, and ADR A549, A549/CDDP N/T [158 ] miR-181b BCL2 Increased sensitivity to a number of anticancer drugs including VCR, 5-Fu, CDDP, VP-16, and ADR A549, A549/CDDP N/T [161 ]